Barclays raised the firm’s price target on Evolus (EOLS) to $22 from $20 and keeps an Overweight rating on the shares as part of a Q4 preview for the specialty pharmaceuticals group. The firm is factoring in higher a probability of success for Evolysse approval.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- TikTok comes back online in U.S., Schwab reports Q4 beat: Morning Buzz
- Evolus sees FY25 revenue $345M-$355M, consensus $347.37M
- Evolus expects FDA approval for Evolysse within 90 days, ahead of schedule
- Evolus reports preliminary Q4 revenue $79M, consensus $77.23M
- Evolus raises FY24 revenue view to $266.3M from $260M-$266M, consensus $264.21M